{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:27Z","timestamp":1791593847950,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a rare, potentially life-threatening autoimmune disease with fluctuating muscle weakness frequently affecting women of childbearing age. MG can affect maternal as well as neonatal outcome with risk of worsening of myasthenic symptoms in the mothers and risk of transient neonatal myasthenia gravis (TNMG) and arthrogryposis multiplex congenita (AMC) or foetal acetylcholine receptor antibody-associated disorders (FARAD) in the neonates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of maternal and neonatal outcome in a cohort of pregnant MG patients treated at a tertiary care centre in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 66 pregnancies were analysed. During 40 (63%) pregnancies, women experienced a worsening of myasthenic symptoms, of whom 10 patients (15.7%) needed acute therapy with IVIg or plasma exchange. There was no case of myasthenic crisis. Rate of caesarean section was comparable to the overall C-section rate at our centre (38% vs. 40%). However, there was a slightly higher rate for operative vaginal delivery (15% vs. 10%) as potential indicator for fatiguing striated musculature in MG patients during the expulsion stage. Rate of TNMG as well as AMC was 3% (two cases each).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Maternal and neonatal outcome in our cohort was favourable with a low rate of myasthenic exacerbations requiring acute therapies and a low rate of TNMG and AMC\/FARAD. Our data might help neurologists and obstetricians to advice MG patients with desire to have children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-024-07436-y","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T04:01:56Z","timestamp":1710561716000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care centre in Germany"],"prefix":"10.1007","volume":"310","author":[{"given":"Jakob","family":"Draxler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Stascheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Gerischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mergenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meret","family":"Herdick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Doksani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lehnerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Verlohren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9549-2594","authenticated-orcid":false,"given":"Sarah","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"issue":"2","key":"7436_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149","journal-title":"Muscle Nerve"},{"issue":"2","key":"7436_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000529583","volume":"57","author":"H Wartmann","year":"2023","unstructured":"Wartmann H, Hoffmann S, Ruck T, Nelke C, Deiters B, Volmer T (2023) Incidence, prevalence, hospitalization rates, and treatment patterns in myasthenia gravis: a 10-year real-world data analysis of german claims data. Neuroepidemiology 57(2):121\u2013128","journal-title":"Neuroepidemiology"},{"key":"7436_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10:46","journal-title":"BMC Neurol"},{"issue":"3","key":"7436_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/mus.24556","volume":"52","author":"S Ohlraun","year":"2015","unstructured":"Ohlraun S, Hoffmann S, Klehmet J, Kohler S, Grittner U, Schneider A et al (2015) Impact of myasthenia gravis on family planning: how do women with myasthenia gravis decide and why? Muscle Nerve 52(3):371\u2013379","journal-title":"Muscle Nerve"},{"issue":"2","key":"7436_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/1753495X211041899","volume":"15","author":"H Banner","year":"2022","unstructured":"Banner H, Niles KM, Ryu M, Sermer M, Bril V, Murphy KE (2022) Myasthenia gravis in pregnancy: systematic review and case series. Obstet Med 15(2):108\u2013117","journal-title":"Obstet Med"},{"issue":"3","key":"7436_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1212\/WNL.52.3.447","volume":"52","author":"AP Batocchi","year":"1999","unstructured":"Batocchi AP, Majolini L, Evoli A, Lino MM, Minisci C, Tonali P (1999) Course and treatment of myasthenia gravis during pregnancy. Neurology 52(3):447\u2013452","journal-title":"Neurology"},{"issue":"1","key":"7436_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0301-2115(02)00051-9","volume":"104","author":"J Djelmis","year":"2002","unstructured":"Djelmis J, Sostarko M, Mayer D, Ivanisevic M (2002) Myasthenia gravis in pregnancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol 104(1):21\u201325","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"7436_CR8","first-page":"144","volume":"107","author":"SA Garcia","year":"1989","unstructured":"Garcia SA, Ogata AJ, Patriota RG, Lippi UG, Grabert HH (1989) Myasthenia gravis and pregnancy: review of the literature and report of 6 cases occurring in 5 patients. Rev Paul Med 107(3):144\u2013148","journal-title":"Rev Paul Med"},{"issue":"2","key":"7436_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/088307389200700202","volume":"7","author":"O Papazian","year":"1992","unstructured":"Papazian O (1992) Transient neonatal myasthenia gravis. J Child Neurol 7(2):135\u2013141","journal-title":"J Child Neurol"},{"issue":"1","key":"7436_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1212\/WNL.38.1.138","volume":"38","author":"E Morel","year":"1988","unstructured":"Morel E, Eymard B, Vernet-der Garabedian B, Pannier C, Dulac O, Bach JF (1988) Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases. Neurology 38(1):138\u2013142","journal-title":"Neurology"},{"issue":"12","key":"7436_CR11","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/ene.13788","volume":"25","author":"NE Gilhus","year":"2018","unstructured":"Gilhus NE, Hong Y (2018) Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol 25(12):1402\u20131409","journal-title":"Eur J Neurol"},{"issue":"5","key":"7436_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","volume":"85","author":"F Norwood","year":"2014","unstructured":"Norwood F, Dhanjal M, Hill M, James N, Jungbluth H, Kyle P et al (2014) Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry 85(5):538\u2013543","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"7436_CR13","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1212\/NXI.0000000000000057","volume":"2","author":"Y Hacohen","year":"2015","unstructured":"Hacohen Y, Jacobson LW, Byrne S, Norwood F, Lall A, Robb S et al (2015) Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies. Neurol Neuroimmunol Neuroinflamm 2(1):e57","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"24","key":"7436_CR14","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1212\/01.wnl.0000336929.38733.7a","volume":"71","author":"M Oskoui","year":"2008","unstructured":"Oskoui M, Jacobson L, Chung WK, Haddad J, Vincent A, Kaufmann P et al (2008) Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis. Neurology 71(24):2010\u20132012","journal-title":"Neurology"},{"key":"7436_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.07.445","author":"NM Allen","year":"2023","unstructured":"Allen NM, O\u2019Rahelly M, Eymard B, Chouchane M, Hahn A, Kearns G et al (2023) The emerging spectrum of foetal acetylcholine receptor antibody-associated disorders (FARAD). Brain. https:\/\/doi.org\/10.1016\/j.nmd.2023.07.445","journal-title":"Brain"},{"key":"7436_CR16","unstructured":"Wiendl HMA et al (2022) Diagnostik and Therapie myasthener Syndrome, S2k-Leitlinie, DGN. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. https:\/\/register.awmf.org\/assets\/guidelines\/030-087l_S2k_Diagnostik-Therapie-myasthener-Syndrome_2023-05.pdf. Accessed 20 Sept 2023"},{"issue":"1","key":"7436_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 55(1):16\u201323","journal-title":"Neurology"},{"issue":"4","key":"7436_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/mus.25095","volume":"54","author":"AC Braga","year":"2016","unstructured":"Braga AC, Pinto C, Santos E, Braga J (2016) Myasthenia gravis in pregnancy: experience of a portuguese center. Muscle Nerve 54(4):715\u2013720","journal-title":"Muscle Nerve"},{"key":"7436_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16100","author":"L O\u2019Connor","year":"2023","unstructured":"O\u2019Connor L, Malmestrom C, Da Silva RR, Brauner S, Wikstrom AK, Punga AR (2023) Pregnancy outcomes for women with myasthenia gravis and their newborns: a nationwide register-based cohort study. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.16100","journal-title":"Eur J Neurol"},{"key":"7436_CR20","unstructured":"2023 [Available from: https:\/\/www.destatis.de\/DE\/Presse\/Pressemitteilungen\/2023\/02\/PD23_N009_231.html#:~:text=WIESBADEN%20%E2%80%93%20Rund%20237%20000%20Frauen,bundesweit%20bei%2030%2C9%20%25."},{"issue":"3","key":"7436_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.c.31723","volume":"181","author":"I Filges","year":"2019","unstructured":"Filges I, Tercanli S, Hall JG (2019) Fetal arthrogryposis: challenges and perspectives for prenatal detection and management. Am J Med Genet C Semin Med Genet 181(3):327\u2013336","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"10","key":"7436_CR22","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1172\/JCI119048","volume":"98","author":"S Riemersma","year":"1996","unstructured":"Riemersma S, Vincent A, Beeson D, Newland C, Hawke S, Vernet-der Garabedian B et al (1996) Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 98(10):2358\u20132363","journal-title":"J Clin Invest"},{"issue":"5","key":"7436_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/1096-9926(200011)62:5<332::AID-TERA7>3.0.CO;2-E","volume":"62","author":"A Polizzi","year":"2000","unstructured":"Polizzi A, Huson SM, Vincent A (2000) Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology 62(5):332\u2013341","journal-title":"Teratology"},{"issue":"1","key":"7436_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/mus.27839","volume":"68","author":"Y Harada","year":"2023","unstructured":"Harada Y, Bettin M, Juel VC, Hobson-Webb LD, Raja SM, Sanders DB et al (2023) Pregnancy in MuSK-positive myasthenia gravis: a single-center case series. Muscle Nerve 68(1):85\u201390","journal-title":"Muscle Nerve"},{"issue":"1","key":"7436_CR25","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1055\/s-0036-1579624","volume":"6","author":"C Townsel","year":"2016","unstructured":"Townsel C, Keller R, Johnson K, Hussain N, Campbell WA (2016) Seronegative maternal ocular myasthenia gravis and delayed transient neonatal myasthenia gravis. AJP Rep 6(1):e133\u2013e136","journal-title":"AJP Rep"},{"issue":"8","key":"7436_CR26","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s00115-010-2995-7","volume":"81","author":"J Klehmet","year":"2010","unstructured":"Klehmet J, Dudenhausen J, Meisel A (2010) Course and treatment of myasthenia gravis during pregnancy. Nervenarzt 81(8):956\u2013962","journal-title":"Nervenarzt"},{"issue":"7","key":"7436_CR27","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nation SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487\u20131489","journal-title":"Neurology"},{"issue":"4","key":"7436_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s004150050585","volume":"247","author":"T Sharshar","year":"2000","unstructured":"Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C et al (2000) Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 247(4):286\u2013290","journal-title":"J Neurol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07436-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-024-07436-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07436-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T08:07:53Z","timestamp":1718179673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-024-07436-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["7436"],"URL":"https:\/\/doi.org\/10.1007\/s00404-024-07436-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3689101\/v1","asserted-by":"object"}]},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jakob Draxler, Andreas Meisel, Frauke Stascheit, Maike Stein, Lea Gerischer, Philipp Mergenthaler, Meret Herdick, Paolo Doksani, Sophie Lehnerer, Stefan Verlohren and Sarah Hoffmann report no conflicts of interest related to the subject matter of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of the Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin (EA2\/006\/22, date 1st of March 2022). All patients contacted via mail for completion of the questionnaire gave written informed consent in accordance with the Declaration of Helsinki in its currently applicable form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}